Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients

Katsuto Takenaka, Tetsuya Eto, Koji Nagafuji, Kenjiro Kamezaki, Yayoi Matsuo, Goichi Yoshimoto, Naoki Harada, Maki Yoshida, Hideho Henzan, Ken Takase, Toshihiro Miyamoto, Koichi Akashi, Mine Harada, Takanori Teshima

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Between March 2007 and January 2008, the safety and efficacy of oral valganciclovir (VGC) preemptive therapy for cytomegalovirus (CMV) infection was evaluated in ten consecutive patients who received allogeneic hematopoietic stem cell transplantation (HSCT). Patients were screened once or twice per week after engraftment using CMV pp65 antigenemia assay. When more than 2 CMV antigen-positive cells per 50,000 leukocytes were detected, preemptive therapy with oral VGC was initiated at a dose of 900 mg twice daily for 3 weeks. Nine patients (90%) completed the 3-week VGC treatment except for one patient who developed febrile neutropenia. There was no other significant toxicity. CMV antigen-positive cells were rapidly decreased in all nine patients and became undetectable by the end of the VGC treatment. None of the patients developed CMV disease. CMV infection relapsed in four of the ten patients (40%) after the VGC treatment. These observations suggest that preemptive therapy with VGC is effective for preventing CMV disease in allogeneic HSCT patients. Further studies with a large number of patients will be necessary to determine the optimal initial- and maintenance-dose of VGC.

Original languageEnglish
Pages (from-to)231-237
Number of pages7
JournalInternational journal of hematology
Volume89
Issue number2
DOIs
Publication statusPublished - Mar 1 2009

Fingerprint

Cytomegalovirus Infections
Hematopoietic Stem Cells
Transplants
Cytomegalovirus
Therapeutics
Hematopoietic Stem Cell Transplantation
valganciclovir
Transplant Recipients
Antigens
Febrile Neutropenia
Leukocytes
Maintenance
Safety

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. / Takenaka, Katsuto; Eto, Tetsuya; Nagafuji, Koji; Kamezaki, Kenjiro; Matsuo, Yayoi; Yoshimoto, Goichi; Harada, Naoki; Yoshida, Maki; Henzan, Hideho; Takase, Ken; Miyamoto, Toshihiro; Akashi, Koichi; Harada, Mine; Teshima, Takanori.

In: International journal of hematology, Vol. 89, No. 2, 01.03.2009, p. 231-237.

Research output: Contribution to journalArticle

Takenaka, Katsuto ; Eto, Tetsuya ; Nagafuji, Koji ; Kamezaki, Kenjiro ; Matsuo, Yayoi ; Yoshimoto, Goichi ; Harada, Naoki ; Yoshida, Maki ; Henzan, Hideho ; Takase, Ken ; Miyamoto, Toshihiro ; Akashi, Koichi ; Harada, Mine ; Teshima, Takanori. / Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. In: International journal of hematology. 2009 ; Vol. 89, No. 2. pp. 231-237.
@article{95add39616ae4aab9832297af597eb08,
title = "Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients",
abstract = "Between March 2007 and January 2008, the safety and efficacy of oral valganciclovir (VGC) preemptive therapy for cytomegalovirus (CMV) infection was evaluated in ten consecutive patients who received allogeneic hematopoietic stem cell transplantation (HSCT). Patients were screened once or twice per week after engraftment using CMV pp65 antigenemia assay. When more than 2 CMV antigen-positive cells per 50,000 leukocytes were detected, preemptive therapy with oral VGC was initiated at a dose of 900 mg twice daily for 3 weeks. Nine patients (90{\%}) completed the 3-week VGC treatment except for one patient who developed febrile neutropenia. There was no other significant toxicity. CMV antigen-positive cells were rapidly decreased in all nine patients and became undetectable by the end of the VGC treatment. None of the patients developed CMV disease. CMV infection relapsed in four of the ten patients (40{\%}) after the VGC treatment. These observations suggest that preemptive therapy with VGC is effective for preventing CMV disease in allogeneic HSCT patients. Further studies with a large number of patients will be necessary to determine the optimal initial- and maintenance-dose of VGC.",
author = "Katsuto Takenaka and Tetsuya Eto and Koji Nagafuji and Kenjiro Kamezaki and Yayoi Matsuo and Goichi Yoshimoto and Naoki Harada and Maki Yoshida and Hideho Henzan and Ken Takase and Toshihiro Miyamoto and Koichi Akashi and Mine Harada and Takanori Teshima",
year = "2009",
month = "3",
day = "1",
doi = "10.1007/s12185-008-0249-2",
language = "English",
volume = "89",
pages = "231--237",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients

AU - Takenaka, Katsuto

AU - Eto, Tetsuya

AU - Nagafuji, Koji

AU - Kamezaki, Kenjiro

AU - Matsuo, Yayoi

AU - Yoshimoto, Goichi

AU - Harada, Naoki

AU - Yoshida, Maki

AU - Henzan, Hideho

AU - Takase, Ken

AU - Miyamoto, Toshihiro

AU - Akashi, Koichi

AU - Harada, Mine

AU - Teshima, Takanori

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Between March 2007 and January 2008, the safety and efficacy of oral valganciclovir (VGC) preemptive therapy for cytomegalovirus (CMV) infection was evaluated in ten consecutive patients who received allogeneic hematopoietic stem cell transplantation (HSCT). Patients were screened once or twice per week after engraftment using CMV pp65 antigenemia assay. When more than 2 CMV antigen-positive cells per 50,000 leukocytes were detected, preemptive therapy with oral VGC was initiated at a dose of 900 mg twice daily for 3 weeks. Nine patients (90%) completed the 3-week VGC treatment except for one patient who developed febrile neutropenia. There was no other significant toxicity. CMV antigen-positive cells were rapidly decreased in all nine patients and became undetectable by the end of the VGC treatment. None of the patients developed CMV disease. CMV infection relapsed in four of the ten patients (40%) after the VGC treatment. These observations suggest that preemptive therapy with VGC is effective for preventing CMV disease in allogeneic HSCT patients. Further studies with a large number of patients will be necessary to determine the optimal initial- and maintenance-dose of VGC.

AB - Between March 2007 and January 2008, the safety and efficacy of oral valganciclovir (VGC) preemptive therapy for cytomegalovirus (CMV) infection was evaluated in ten consecutive patients who received allogeneic hematopoietic stem cell transplantation (HSCT). Patients were screened once or twice per week after engraftment using CMV pp65 antigenemia assay. When more than 2 CMV antigen-positive cells per 50,000 leukocytes were detected, preemptive therapy with oral VGC was initiated at a dose of 900 mg twice daily for 3 weeks. Nine patients (90%) completed the 3-week VGC treatment except for one patient who developed febrile neutropenia. There was no other significant toxicity. CMV antigen-positive cells were rapidly decreased in all nine patients and became undetectable by the end of the VGC treatment. None of the patients developed CMV disease. CMV infection relapsed in four of the ten patients (40%) after the VGC treatment. These observations suggest that preemptive therapy with VGC is effective for preventing CMV disease in allogeneic HSCT patients. Further studies with a large number of patients will be necessary to determine the optimal initial- and maintenance-dose of VGC.

UR - http://www.scopus.com/inward/record.url?scp=67349147874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349147874&partnerID=8YFLogxK

U2 - 10.1007/s12185-008-0249-2

DO - 10.1007/s12185-008-0249-2

M3 - Article

C2 - 19148587

AN - SCOPUS:67349147874

VL - 89

SP - 231

EP - 237

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 2

ER -